Daxor Unveils Portable Blood Volume Analyzer at SCCM 2026
Event summary
- Daxor will debut a portable blood volume analyzer at SCCM 2026 Critical Care Congress (March 22–24).
- Device delivers rapid, lab-quality results for easier ICU implementation.
- BVA has shown 66% mortality reduction in surgical ICUs per peer-reviewed studies.
- U.S. ICU admissions exceed 5M annually, costing over $100B in healthcare spending.
The big picture
Daxor's portable analyzer targets the $100B+ U.S. ICU market by enabling precision fluid management. The device's rapid results could accelerate adoption in high-cost settings where suboptimal care drives prolonged stays. Success hinges on proving sustained mortality reductions in diverse clinical environments.
What we're watching
- Adoption Pace
- How quickly hospitals integrate portable BVA into ICU workflows.
- Outcome Validation
- Whether real-world results match peer-reviewed mortality reductions.
- Market Expansion
- The pace at which Daxor scales beyond U.S. critical care settings.
Related topics